PCRX Stock Overview
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PCRX from our risk checks.
Pacira BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.03 |
| 52 Week High | US$35.95 |
| 52 Week Low | US$11.16 |
| Beta | 0.82 |
| 11 Month Change | -1.73% |
| 3 Month Change | 21.90% |
| 1 Year Change | -36.19% |
| 33 Year Change | -68.61% |
| 5 Year Change | -62.69% |
| Change since IPO | 142.59% |
Recent News & Updates
Recent updates
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14Shareholder Returns
| PCRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.5% | -3.8% | -1.0% |
| 1Y | -36.2% | 9.8% | 30.3% |
Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: PCRX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| PCRX volatility | |
|---|---|
| PCRX Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PCRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 712 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
Pacira BioSciences, Inc. Fundamentals Summary
| PCRX fundamental statistics | |
|---|---|
| Market cap | US$772.48m |
| Earnings (TTM) | -US$90.73m |
| Revenue (TTM) | US$694.96m |
1.1x
P/S Ratio-8.7x
P/E RatioIs PCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCRX income statement (TTM) | |
|---|---|
| Revenue | US$694.96m |
| Cost of Revenue | US$255.38m |
| Gross Profit | US$439.58m |
| Other Expenses | US$530.31m |
| Earnings | -US$90.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 63.25% |
| Net Profit Margin | -13.06% |
| Debt/Equity Ratio | 78.4% |
How did PCRX perform over the long term?
See historical performance and comparison